Search International and National Patent Collections
Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2014177676) FENFLURAMINE FOR USE IN THE TREATMENT OF DRAVET SYNDROME
Note: Text based on automatic Optical Character Recognition processes. Please use the PDF version for legal matters

CLAIMS

1 . A method of treating and / or preventing Dravet Syndrome in a patient comprising administering an effective dose of fenfluramine or a pharmaceutically acceptable salt thereof to said patient.

2. A method of treating, preventing and / or ameliorating seizures in a patient diagnosed with Dravet Syndrome comprising administering an effective dose of fenfluramine or a pharmaceutically acceptable salt thereof to said patient.

3. A method of treating a patient exhibiting a mutation in one, some or all of the genes selected from the group consisting of SCN1 A, SCN1 B, SCN2A, SCN3A, SCN9A, GABRG2, GABRD and PCDH19 by administering to said patient an effective dose of fenfluramine or a pharmaceutically acceptable salt thereof.

4. A method of stimulating one or more 5-HT receptors in the brain of a patient by administering an effective dose of fenfluramine or a pharmaceutically acceptable salt thereof to said patient, said one or more 5-HT receptors being selected from the group consisting of one or more of 5-HT1 ; 5-HT1A, 5-HT1 B, 5-HT1 G, 5-HT1 D, 5-HT1 E, 5-HT1 F, 5-HT2, 5-HT2A, 5-HT2B, 5-HT2C, 5-HT3, 5-HT4, 5-HT5, 5-HT5A, 5-HT5B 5-HT6, and 5-HT7.

5. The method of Claim 3 or 4 wherein said patient has been diagnosed with Dravet Syndrome.

6. The method of any one of Claims 1 to 5, wherein the effective dose is less than about 0.5 mg/kg/day to about 0.01 mg/kg/day.

7. The method of any one of Claims 1 to 6, wherein the effective dose is administered in the form of one or more dosage forms for oral, injectable, transdermal, inhaled, nasal, rectal, vaginal or parenteral delivery.

8. The method of Claim 7, wherein the one or more dosage forms are liquid formulations.

9. The method of any one of Claims 1 to 8, wherein fenfluramine is employed as a monotherapy.

10. The method of any one of Claims 1 to 8, wherein the effective dose of fenfluramine or a pharmaceutically acceptable salt thereof is coadministered with one or more co-therapeutic agents.

1 1 . The method of Claim 10, wherein the one or more co-therapeutic agents is selected from the group consisting of carbamazepine, ethosuximide, fosphenytoin, lamotrigine, levetiracetam, phenobarnitol, progabide, topiramate, stiripentol, valproic acid, valproate, verapamil, and benzodiazepines such as clobazam, clonazepam, diazepam, ethyl loflazepate, lorazepam, and midazolam or a pharmaceutically acceptable salt thereof.

12. The method of any one of Claims 1 to 1 1 , wherein said patient is aged 18 or less.

13. A composition comprising fenfluramine for use in the methods of any one of Claims 1 to 12.

14. The use of fenfluramine in the manufacture of a medicament for use in the methods of any one of Claims 1 to 12.

15. A kit comprising an effective dose of fenfluramine and instructions for using said dose in the methods of any one of Claims 1 to